Piper Sandler initiated coverage of Merus (MRUS) with an Overweight rating and $84 price target The firm views the company’s EGFRxLGR5 bispecific, petosemtamab, as “significantly de-risked ...
Merus N.V. announced progress on its clinical trials involving petosemtamab, designed for treating recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) and metastatic colorectal ...
MRUS opened at $47.58 on Monday. Merus has a 52-week low of $37.77 and a 52-week high of $61.61. The firm has a market capitalization of $3.29 billion, a PE ratio of -12.05 and a beta of 1.15. The ...
Merus (NASDAQ:MRUS – Get Free Report) saw a large drop in short interest in the month of February.As of February 15th, there was short interest totalling 6,640,000 shares, a drop of 13.5% from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback